Evaluation of PD-L1, PD-L2, PD-1 and cytotoxic immune response in oral lichen planus

被引:13
|
作者
Costa, Nadia Lago [1 ]
Goncalves, Julie Ane Maria [1 ]
de Lima, Sara Lia Goncalves [1 ]
de Arruda, Jose Alcides Almeida [2 ]
Miranda, Ana Carolina Campos [1 ]
Mesquita, Ricardo Alves [1 ,2 ]
da Silveira, Ericka Janine Dantas [3 ]
Batista, Aline Carvalho [1 ]
机构
[1] Univ Fed Goias, Sch Dent, Dept Stomatol Oral Med & Oral Pathol, Praca Univ S-N,Setor Univ, BR-74605220 Goiania, Go, Brazil
[2] Univ Fed Minas Gerais, Sch Dent, Dept Oral Surg & Pathol, Belo Horizonte, MG, Brazil
[3] Univ Fed Rio Grande do Norte, Dept Dent, Postgrad Program Odontol Sci, Natal, RN, Brazil
关键词
immunogenicity; immunohistochemical; lichen planus; mouth diseases; programmed cell death-1 ligand-2 protein; T-lymphocyte receptor; MALIGNANT-TRANSFORMATION; T-CELLS; EVASION MECHANISMS; EXPRESSION; MICROENVIRONMENT; PATHWAY; LESIONS; B7-DC;
D O I
10.1111/odi.13344
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objective To investigate the expression of programmed death-ligands 1 and 2 (PD-L1, PD-L2), programmed death-1 (PD-1), CD8 and granzyme B (GrB), as well as its correlation with the severity of oral lichen planus (OLP). Materials and Methods In a collaborative study, 33 cases of OLP were evaluated according to the latest criteria proposed by the American Academy of Oral and Maxillofacial Pathology (AAOMP/2016) and were submitted to immunohistochemistry. Positivity was measured semiquantitatively (PD-L1, PD-L2) and quantitatively (PD-1, CD8, GrB). The severity of OLP was assessed according to clinical subtype, symptomatology and response to corticosteroid therapy. Results Most OLPs were considered to be negative for PD-L1 (66.6%), but high expression of PD-L2 (96.9%) by keratinocytes and immunoinflammatory cells was observed. PD-1(+) cell density/mm(2) was reduced compared to CD8(+) cells. A low cytotoxic immune response (CD8:GrB ratio) was also demonstrated. Interestingly, there were fewer GrB(+) cells in the intraepithelial region in reticular OLP compared to erosive/bullous OLP. Conclusions PD-L1/PD-1 pathways appear to be compromised in OLP due to low PD-L1 expression in most samples. In contrast, PD-L2 overexpression associated with a possible regulation of the cytotoxic immune response suggests an immune tolerance that may contribute to the chronic profile of OLP.
引用
收藏
页码:1246 / 1254
页数:9
相关论文
共 50 条
  • [21] The PD-1 pathway in systemic lupus erythematosus: The Ligands of PD-1, PD-L1 and PD-L2, are also susceptibility factors.
    Abelson, AK
    Johansson, C
    Kozyrev, S
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S203 - S203
  • [22] Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis
    Suszczyk, Dorota
    Skiba, Wiktoria
    Zardzewialy, Witold
    Pawlowska, Anna
    Wlodarczyk, Karolina
    Polak, Grzegorz
    Tarkowski, Rafal
    Wertel, Iwona
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (19)
  • [23] PD-1, PD-L1, and PD-L2 Gene Expression and Tumor Infiltrating Lymphocytes in Canine Melanoma
    Stevenson, Valentina B.
    Perry, Samantha N.
    Todd, Michelle
    Huckle, William R.
    LeRoith, Tanya
    VETERINARY PATHOLOGY, 2021, 58 (04) : 692 - 698
  • [24] AKT/mTOR Signal Cascade and Expression of PD-1, PD-L1, and PD-L2 in Gastric Cancer
    Spirina, L. V.
    Avgustinovich, A. V.
    Afanas'ev, S. G.
    Kondakova, I. V.
    Volkov, M. Yu.
    Dobrodeev, A. Yu.
    Boronkina, A. I.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2020, 170 (01) : 75 - 78
  • [25] Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
    Jiang, Siqing
    Li, Xin
    Huang, Lihua
    Xu, Zhensheng
    Lin, Jinguan
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [26] EXPRESSION OF PD-1, PD-L1 AND PD-L2 IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND ITS CLINIC RELATIONSHIP
    Geng, S.
    Weng, J.
    Deng, C.
    Li, M.
    Lu, Z.
    Wu, P.
    Huang, X.
    Lai, P.
    Du, X.
    LEUKEMIA RESEARCH, 2017, 55 : S112 - S112
  • [27] High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2
    Li, Yanyan
    Liang, Zhaoduan
    Tian, Ye
    Cai, Wenxuan
    Weng, Zhiming
    Chen, Lin
    Zhang, Huanling
    Bao, Yifeng
    Zheng, Hongjun
    Zeng, Sihai
    Bei, Chunhua
    Li, Yi
    CANCER SCIENCE, 2018, 109 (08): : 2435 - 2445
  • [28] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
    Bai, Jie
    Gao, Zhitao
    Li, Xiang
    Dong, Liang
    Han, Weidong
    Nie, Jing
    ONCOTARGET, 2017, 8 (66) : 110693 - 110707
  • [29] The role of antagonists of the PD-1: PD-L1/PD-L2 axis in head and neck cancer treatment
    Pai, Sara I.
    Zandberg, Dan P.
    Strome, Scott E.
    ORAL ONCOLOGY, 2016, 61 : 152 - 158
  • [30] Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
    Spirina, Liudmila
    Yurmazov, Zahar
    Usynin, Evgeny
    Kondakova, Irina
    Ladutko, Ekaterine
    Choynzonov, Evgeny
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2021, 43 (02) : 1072 - 1080